Lymphocytes from the synovial fluid of eight out of eight rheumatoid arthritis (RA) patients had elevated very late activation antigen-i (VLA-1) expression (10-36% positive cells), whereas peripheral blood lymphocytes (PBL) from RA patients and healthy controls had low VLA-1 expression (0-6% positive cells). Mr) on synovial lymphocytes, and thus the VLA-1/VLA-2 ratio is another indicator of the stage of T cell activation.
Introduction
Several activation antigens known to appear in vitro have been measured in vivo on T cells from patients with rheumatoid arthritis (RA)I in order to further understand the role ofactivated T cells in disease. T cells bearing elevated levels of the class II (Ia) activation antigens have been found in peripheral blood (1, 2) , synovial fluid, and synovium ofpatients with this disease (2, 3) . Other activation markers, including OKT1O (4), T305 (5) , and interleukin 2 receptor (IL-2 R) (6) , have also been found on synovial T cells in RA. These results are consistent with the hypotheses that tissue injury in RA involves activated T cells. cells. Normal T lymphoblasts obtained from in vitro mitogen stimulation were found to contain transferrin receptors (7) , were blastoid, and had more IL-2 R than Ia (6) . In contrast, synovial T cells did not have detectable transferrin receptors (4), were largely nonblastoid, and had a greater elevation of Ia than IL-2 R (6) .
Additional antigens associated with T cell activation have now been described. The very late activation antigen-l (VLA-1) appears slowly on activated T cells in vitro and is not highly expressed until 2-3 wk after initial T cell stimulation, well after both proliferation and IL-2 R levels have diminished (8) (9) (10) . On the other hand, conditions of increased T cell stimulation and proliferation corresponded to decreased VLA-l expression at the same time that a large number of other cell surface activation antigens (such as Ia, transferrin receptor, 4F2 antigen, and OKT1O antigen) were elevated (Hemler, M. E., and J. G. Jacobson, manuscript submitted for publication). Thus it has been suggested that the 210,000/130,000 relative molecular mass (Mr) heterodimer VLA-l may define a novel very late stage of activation that is phenotypically and functionally distinct from the earlier stages of activation (8) (9) (10) , and that VLA-l is not really an activation antigen, but perhaps is better called a postactivation antigen (Hemler, M. E., and J. G. Jacobson, manuscript submitted for publication).
The 210,000/130,000 M, VLA-l heterodimer is part of a larger family of proteins that includes another long-term T cell protein complex called VLA-2 (165,000/130,000 Mr). Biochemical studies have shown that these structures are noncovalently linked heterodimers with unique a and common # subunits (1 1) . Conditions that cause changes in VLA-l expression generally had an opposite effect on VLA-2 expression. Thus, T cell stimulation with antigen, mitogen, or in some instances IL-2 resulted in a decreased VLA-I/VLA-2 ratio, whether by decreasing VLA-1, increasing VLA-2, or by doing both at once (Hemler, M. E., and J. G. Jacobson, manuscript submitted for publication).
The unusually late appearance of VLA-l compared with other antigens appearing on activated T cells suggested that this marker will be especially useful for analyzing the characteristics of T lymphocytes involved in the chronic inflammation of RA. Studies to determine the extent of VLA-I (and VLA-2) expression on peripheral blood and synovial fluid lymphocytes from RA patients in the context ofT cell activation are reported herein.
Methods
Peripheral blood and synovial fluid samples. Blood and synovial fluid samples were obtained from RA patients undergoing long-term followup drawn during the same clinic visit in five of the patients studied. Additional blood samples were drawn from healthy volunteers.
Antibodies. The monoclonal antibody (MAb) TS2/7 (IgG1) recognizes the 210,000/130,000 Mr VLA-l complex (9, 1 1). The MAb A-lA5 (IgG2b) recognizes the 130,000 Mr subunit common to both VLA-2 (165,000/130,000 M,) and VLA-1 (8, 1 1). The expression of IL-2 R was analyzed using the MAb 49.9 (13) and T3 was analyzed using OKT3 from Ortho Pharmaceutical, Raritan, NJ. The negative control MAb P3 (IgGI) is the antibody secreted by the myeloma line P3-X63Ag8 (14) .
T cell samples, in vitro cell cultures, and mitogen stimulation. The synovial fluid was suspended in 10 vol ofphosphate-buffered saline (PBS), centrifuged, and the cell pellet was then enriched for mononuclear cells by Ficoll-Hypaque separation. Blood samples were also enriched for mononuclear cells by Ficoll-Hypaque separation. For in vitro culture, IL-2 (1-2 U/ml as defined by Gillis et al. [ 15] ) was added to all cultures two times per week. IL-2 was prepared from culture supernatant resulting from 3-d phytohemagglutinin (PHA) stimulation of peripheral blood lymphocytes (PBL), and partially purified by ammonium sulfate fractionation (16) . PHA (Difco Laboratories, Inc., Detroit, MI) diluted 1/1000 was used to stimulate T cell cultures where indicated.
Quantitation ofcell surface antigens and cell cycle analysis. Viable cells (1-5 X I0O) from Ficoll-Hypaque centrifugation were suspended in 50-Ml aliquots of PBS containing 0.5% bovine serum albumin and 50% human serum to block nonspecific MAb binding. Then specific mouse MAb (1 Mg in 50 Ml) was added, cells were incubated 30 min at 00C, washed two times, and then incubated with saturating amounts of fluorescein-conjugated F(ab')2 goat anti-mouse Ig. After further washing (three times), fluorescence was quantitated using either a fluorescenceactivated cell sorter analyzer (Becton-Dickinson & Co., Mountain View, CA) or an EPICS V flow cytometer (Coulter Electronics, Inc., Hialeah, FL). Volume gates were set to maximize lymphocyte counting (verified by OKT3 analysis) and to minimize interference from other cell types, such as monocytes or granulocytes. The channel numbers corresponding to median fluorescence intensity on a log scale were converted to linear numbers using a standard curve and the negative control fluorescence was then subtracted. A measure of 1.0 U of this median fluorescence intensity (MFI) is approximately equivalent to 50,000 sites per cell. The percent positive cells was determined as (SP -C)/(T -C) X 100 where SP equals specifically stained cells, C equals negative control staining, and T equals total cells counted. Values for SP and C were taken as the number of cells to the right of the point midway down the C peak. Because the intensity of TS2/7 binding was sometimes rather low (e.g., Fig. 1 ), it is important to note that TS2/7 is the same subclass (IgG 1) as the negative control MAb (P3) and both TS2/7 and P3 were from the same source (culture supernatant) and used at the same concentration.
For cell cycle analysis, cells were permeabilized by treatment with 70% ethanol (30 min, 0°C), washed in PBS, and then stained with propidium iodide (10 Mg/ml) added to 5 X 106 cells in 0.5 ml. Red DNA staining was quantitated using an EPICS V flow cytometer. Iodination and immunoprecipitation of cell surface proteins. Cells were labeled with 1251I using chloroglycoluril, and then 1% Nonidet-P40 cell lysates were used for immunoprecipitation as previously described (8, 9 (Fig. 3 ). In most cases the level of VLA-1 expression was greatly amplified during culture (compare Figs.  3 and 1) . Analyses ofseveral synovial fluid samples during 3 wk ofin vitro culture showed the increase in VLA-l expression was a consistent finding, but this elevation of VLA-1 was not necessarily maintained in culture, since it was followed by a marked decline during some experiments (Fig. 4) .
In contrast, IL-2 R expression on these cultured RA synovial fluid lymphocytes was markedly lower than VLA-1 expression (Fig. 3 , left panels), and was not appreciably elevated on any of the samples tested (Fig. 4) . These cells were not rapidly dividing (data not shown), which is consistent with their low IL-2 R expression. However, when control PBL T cells were cultured for 5 d, the opposite result was obtained. Such cultures readily increased in cell numbers, had elevated IL-2 receptor, and had low expression of VLA-I (Fig. 3, right panels) . In the additional examples shown (Fig. 4) , control and RA PBL cultures both had elevated IL-2 R and low VLA-l levels.
The effect ofPHA stimulation on synovialfluid T cell VLA-1 expression. The expression of elevated VLA-l but not IL-2 R on synovial fluid T cells (Figs. 1-4 pressed compared with an identical culture without PHA (Fig.  5) . In another experiment, PHA was added after synovial fluid T cells had already been cultured for 24 d in vitro (Fig. 6) . In that instance, VLA-l (which had been elevated) disappeared by day 33, whereas IL-2 R (which was absent) became prominent by day 33. In experiments such as the one shown in Fig. 6 Fig. 6 ) the level of IL-2 R expression was markedly elevated after mitogen stimulation (data not shown). At the same time that VLA-I and IL-2 R analyses were carried out (Fig. 6 ), cells were also analyzed for cell cycle distribution using propidium iodide. The results on day 33 indicated that 32% of the PHA-restimulated cells were in the proliferative phases of the cell cycle (S, G2, M) whereas the nonrestimulated cells had only 9% in those cell cycle phases. These results confirm that PHA had a mitogenic effect on cultured synovial T cells, and that VLA-I was present on the less proliferative cells.
Cells cultured for 11 d in the absence of PHA (Fig. 5 ) appeared to be '30% negative for T3. At the same time, those cells appeared to be 100% positive for VLA-1. These results suggest that although VLA-l expression has only been described on activated T cells in vitro (2, 3) , in at least some cases VLA-1 expression is not limited to T3 positive lymphoid cells.
Immunoprecipitation of VLIA-i from synovialfluid T cells.
Immunoprecipitation of VLA-1 on synovial fluid T cells was carried out to verify independently the cell surface binding results (Figs. 1-6) , and also to allow simultaneous comparisons of VLA-I and VLA-2 expression. The Mab A-lA5 was used in these studies because it binds to the common # subunit ofboth VLA-1 and VLA-2 and thus immunoprecipitates both structures at once. The al protein of VLA-1 (210,000/130,000 Mr) along with the detectable a2 protein of VLA-2 (160,000/130,000 Mr) was readily immunoprecipitated from freshly isolated synovial fluid cells (Fig. 7 A, lane a) . Immunoprecipitations of other synovial fluid samples gave similar results (data not shown). In contrast to the result in Fig. 7 (lane a) (Fig. 7 B, 
Discussion
The results in this paper demonstrate that VLA-1, an antigen associated with late stages of T cell activation, is expressed on synovial fluid cells from patients with RA. In contrast to the joint findings, VLA-l was not found on PBL from either RA patients or from controls. The observation of VLA-I positive T cells in the synovium, but not in the peripheral blood of RA patients, supports the concept that synovial T cells represent a distinct compartmentalized population separate from PBL. This is in agreement with other studies that have shown major phenotypic and functional differences between those T cell populations (3, 17, 18) . Earlier studies in vitro have shown that VLA-l was rarely present on mitogen-stimulated T cell blasts until after the levels of blast-associated structures, such as IL-2 R and transferrin receptor, had diminished. Thus it seems likely that VLA-I defines a new stage of late activation on T cells (10, 19) . In this context it is noteworthy that the IL-2 R was present on synovial fluid lymphocytes to a much lesser degree than VLA-1. This suggests that the synovial fluid lymphocyte in RA is activated late and differs from other more blastogenic forms of activated T lymphocytes. Such an interpretation is consistent with the results ofother studies that have shown that Ia-positive synovial T cells from RA patients are nonblastoid, and negative for transferrin receptors, with only weakly elevated IL-2 receptors (4, 6).
These initial observations prompted fiurther investigation into the expression of VLA-I during cell culture. When freshly obtained, a substantial percentage of synovial fluid T cells were positive for VLA-1 but the amount per cell was low. However, in vitro culture of synovial fluid T cells in IL-2 often caused a dramatic increase in the amount of VLA-1 per cell, while the level of IL-2 R did not increase appreciably. A possible interpretation of this result is that the in vivo-derived cells were poised so that in vitro conditions would cause the cells to progress further into the VLA-l-positive late-activation stage. The increase in VLA-1 during in vitro culture also affirms that these cells are fully capable of synthesizing VLA-1 rather than acquiring it from some other cell source. Even though the expression of IL-2 R remained low on cultured synovial T cells these cells still required IL-2 for maintenance of in vitro viability, since removal of IL-2 caused cell death. Nonetheless, the continued lack of expression of substantial levels of IL-2 R suggests that these cells are not being reactivated in culture. This finding appears to be consistent with previous reports that have indicated that synovial T cells are relatively insensitive to in vitro activation, whether by mitogens (20) or by autologous stimulator cells (17). Interestingly, in some in vitro culture experiments, the high levels of VLA-1 expression were transient, suggesting additional in vitro regulation (down as well as up) of VLA-l expression. At present the precise conditions or factors regulating these changes in VLA-I are not understood.
In contrast to synovial fluid T cells, PBL did not express markedly elevated VLA-1 during the first few weeks of in vitro culture. This is in agreement with previous results showing delayed VLA-l expression on in vitro cultured T cells (8) (9) (10) . Also in contrast to synovial fluid T cells, variably elevated IL-2 receptor expression was seen, indicating that in vitro activation was occurring. The exact nature of this activation was not analyzed, but it probably represents some form of lymphokineactivated killer cell selection (21) 
